Literature DB >> 15781060

Maturation but not survival of dopaminergic nigrostriatal neurons is affected in developing and aging BDNF-deficient mice.

Sarah A Baker1, Lianne E Stanford, Richard E Brown, Theo Hagg.   

Abstract

Brain-derived neurotrophic factor (BDNF) promotes survival of injured dopaminergic nigrostriatal neurons of the adult rodent substantia nigra pars compacta, as well their development in vitro. BDNF deficiency may play a role in Parkinson's disease, as the surviving dopaminergic nigrostriatal neurons have reduced levels of BDNF, and a BDNF gene polymorphism is present in a subpopulation of patients. Here, we investigated whether a lack of BDNF in early postnatal BDNF-/- mice or a chronic 50% reduction in BDNF levels in aging BDNF+/- mice would affect the survival of the dopaminergic nigrostriatal neurons. In general terms, BDNF-/- and BDNF+/- mice had morphologically and quantitatively normal nigrostriatal neurons at any time between postnatal day 14 (P14) and 18 months, when compared to their wild-type littermates. BDNF-/- mice (P14 and P21 only) had fewer dopaminergic dendrites in the substantia nigra, suggesting that BDNF plays a role in phenotypic maturation, but not in neuronal birth or survival. BDNF-/- mice also had aberrant tyrosine hydroxylase (TH) positive cell bodies in the pars reticulata. During adulthood and aging, BDNF+/- mice performed equally well as their wild-type littermates in tests of motor coordination, and both showed aging-related decreases in the size of the dopaminergic neurons as well as in motor coordination. These results suggest that chronic deficits in BDNF alone do not affect survival or function of dopaminergic nigrostriatal neurons during aging or potentially even in Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15781060     DOI: 10.1016/j.brainres.2005.01.052

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  21 in total

1.  Effects of brain-derived neurotrophic factor on dopaminergic function and motor behavior during aging.

Authors:  H A Boger; P Mannangatti; D J Samuvel; A J Saylor; T S Bender; J F McGinty; A M Fortress; V Zaman; P Huang; L D Middaugh; P K Randall; L D Jayanthi; B Rohrer; K L Helke; A-C Granholm; S Ramamoorthy
Journal:  Genes Brain Behav       Date:  2010-10-19       Impact factor: 3.449

2.  Dissecting the involvement of tropomyosin-related kinase A and p75 neurotrophin receptor signaling in NGF deficit-induced neurodegeneration.

Authors:  Simona Capsoni; Cecilia Tiveron; Domenico Vignone; Gianluca Amato; Antonino Cattaneo
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-21       Impact factor: 11.205

3.  Brain-derived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta.

Authors:  Zachary C Baquet; Paula C Bickford; Kevin R Jones
Journal:  J Neurosci       Date:  2005-06-29       Impact factor: 6.167

4.  Drug-induced activation of dopamine D(1) receptor signaling and inhibition of class I/II histone deacetylase induce chromatin remodeling in reward circuitry and modulate cocaine-related behaviors.

Authors:  Frederick A Schroeder; Krista L Penta; Anouch Matevossian; Sara R Jones; Christine Konradi; Andrew R Tapper; Schahram Akbarian
Journal:  Neuropsychopharmacology       Date:  2008-02-20       Impact factor: 7.853

Review 5.  Drug Targets in Neurotrophin Signaling in the Central and Peripheral Nervous System.

Authors:  Mahendra Pratap Kashyap; Callie Roberts; Mohammad Waseem; Pradeep Tyagi
Journal:  Mol Neurobiol       Date:  2018-01-25       Impact factor: 5.590

6.  Brain-derived neurotrophic factor regulates early postnatal developmental cell death of dopamine neurons of the substantia nigra in vivo.

Authors:  Tinmarla F Oo; Deanna M Marchionini; Olga Yarygina; Paul D O'Leary; Richard A Hughes; Nikolai Kholodilov; Robert E Burke
Journal:  Mol Cell Neurosci       Date:  2009-05-03       Impact factor: 4.314

7.  Dysregulation of TrkB phosphorylation and proBDNF protein in adenylyl cyclase 1 and 8 knockout mice in a model of fetal alcohol spectrum disorder.

Authors:  Laura L Susick; Alexandria C Chrumka; Steven M Hool; Alana C Conti
Journal:  Alcohol       Date:  2016-01-12       Impact factor: 2.405

8.  BDNF deficiency and enriched environment treatment affect neurotransmitter gene expression differently across ages.

Authors:  Brittany E Dong; Hao Chen; Kazuko Sakata
Journal:  J Neurochem       Date:  2020-06-12       Impact factor: 5.372

9.  Cognition Enhancing and Neuromodulatory Propensity of Bacopa monniera Extract Against Scopolamine Induced Cognitive Impairments in Rat Hippocampus.

Authors:  M D Pandareesh; T Anand; Farhath Khanum
Journal:  Neurochem Res       Date:  2015-12-16       Impact factor: 3.996

Review 10.  NTS-Polyplex: a potential nanocarrier for neurotrophic therapy of Parkinson's disease.

Authors:  Daniel Martinez-Fong; Michael J Bannon; Louis-Eric Trudeau; Juan A Gonzalez-Barrios; Martha L Arango-Rodriguez; Nancy G Hernandez-Chan; David Reyes-Corona; Juan Armendáriz-Borunda; Ivan Navarro-Quiroga
Journal:  Nanomedicine       Date:  2012-03-07       Impact factor: 5.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.